You are here: Industry Insights > Market News > News of Note—Seqirus, VBI and Altimmune

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

Avatrombopag Maleate

BioHub® Magnetic Separator

Avatrombopag

Ursodeoxycholic acid

Troxerutin

CytoLinX® BRTF Single-use Top-driven Bioreactor Bag

News of Note—Seqirus, VBI and Altimmune

fiercepharmaAugust 23, 2017

Tag: Seqirus , VBI , Altimmune

Favorites

> The U.K.’s Medicines and Healthcare products Regulatory Agency has cleared Seqirus’ adjuvanted trivalent influenza vaccine Fluad for use in people aged 65 years or older, 20 years after it was made available in other European countries.

> The FDA has accepted VBI Vaccines’ investigational new drug application for VBI-1901, an immunotherapy targeting glioblastoma multiforme.

> Altimmune submitted an IND application for its intranasally administered recombinant flu vaccine candidate NasoVAX.

Previous:GlaxoSmithKline partners with Alibaba for China HPV vaccine market grab

Next:Hong Kong, S.A.R., China doctor found giving expired flu vaccines to patients

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

PharmaSourcesNovember 22, 2024

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, today opened its new Center for Bioprocess Innovation in Marlborough, Massachusetts.

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

News of Note—Seqirus, VBI and Altimmune | Pharmasources.com

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Discover how AI in pharmacovigilance improves drug safety by predicting risks, identifying harmful interactions, and enhancing patient outcomes.

News of Note—Seqirus, VBI and Altimmune

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

You may like
More>>

News of Note—Seqirus, VBI and Altimmune

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

You may likeMore>>

You may like
More>>